News & Updates | The Sage Group

Sage Group News

Sage Represents DBM: An Opportunity to Acquire or Partner with a Revenue Generating Pre-Clinical CRO

The Sage Group is pleased to announce it is representing Discovery Biomed (“DBM”; https://discoverybiomed.com/). DBM is a...

The Sage Group Expands Team in Japan with Hideyuki Hirama of Gemseki in Tokyo As Partner

London, New York and Tokyo, July 6 2020 - The Sage Group Inc. today announced that Gemseki Japan, led by Hideyuki Hirama, will join its...

Sage Represents Cancer Prevention Pharmaceuticals: A Late Stage, $Billion Orphan Product Opportunity

Sage’s client, Cancer Prevention Pharmaceuticals (“CPP”; www.canprevent.com),is a late clinical stage company developing a unique, oral,...

Sage Group Represents Squarex's SQX770: A Novel Immunologic Approach for the Prevention of Cold

The Sage Group is pleased to announce it has been appointed to represent a product from Squarex LLC, SQX770, the only product which...

The Sage Group Expands Team in North America – Dr. Christine T. Fischette Joins as New Executive Dir

London, England and New York, February 17 2020 - The Sage Group Inc. today announced that Dr. Christine T. Fischette will join the firm...

OncoSec Announces Closing of the CGP/Sirtex Transaction

SAN DIEGO & PENNINGTON, N.J.--(BUSINESS WIRE)-- OncoSec Medical Incorporated (NASDAQ:ONCS) (the “Company” or “OncoSec”), a company...

The Sage Group Expands Team – Dr. Clarissa Ceruti Joins As Executive Director

London, England and New York, February 5 2020 - The Sage Group, Inc. today announced that Dr. Clarissa Ceruti will join the firm as an...

Sage Represents Trecondi® from Medac GmbH: Novel Product for Conditioning in AML and MDS Patients:O

Sage Group is working with medac GmbH who have developed Trecondi®, (Treosulfan), as a superior drug in conjunction with fludarabine...